Novartis's Jakavi gets EU polycythemia vera indication
This article was originally published in Scrip
The European Commission has approved Novartis's oral JAK 1 and 2 tyrosine kinase inhibitor Jakavi (ruxolitinib) for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea, making it the first targeted treatment approved in the EU for this patient population. The approval adds to that already received for the product in the EU and elsewhere for myelofibrosis, and follows the December supplemental approval for polycythemia vera in the US, where it is marketed by Incyte as Jakafi. The polycythemia vera approvals were based on data from the Phase III RESPONSE trial in which the drug significantly improved hematocrit as well as symptom control and reduced spleen size in patients with the rare and incurable blood cancer who were resistant to or intolerant of hydroxyurea. The EU application received a positive opinion from the CHMP in January.
You may also be interested in...
Sanofi/Regeneron’s anti-PD-1 product Libtayo may be late to the NSCLC party but strong data from EMPOWER-Lung 1 suggest it could gain traction in the space, especially in patients with high PD-L1 expression levels.
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
Two different outcomes for two different CD4/6 inhibitors – Eli Lilly’s Verzenio and Pfizer’s Ibrance – put the Lilly drug on track to be a new standard of care in high-risk early stage HR+, HER2-negative breast cancer. Novartis’s Kisqali could follow.